We are live on ! Find out more
BC

Birchview Capital Portfolio holdings

AUM $176M
1-Year Est. Return 95.04%
This Fund
S&P 500
This Quarter Est. Return
+6.36%
1 Year Est. Return
+95.04%
3 Year Est. Return
+233.14%
5 Year Est. Return
+280.2%
10 Year Est. Return
+1,023.63%
AUM
$123M
AUM Growth
-$5.11M
Cap. Flow
-$4.27M
Cap. Flow %
-3.48%
Top 10 Hldgs %
68.23%
Holding
60
New
2
Increased
7
Reduced
2
Closed
1

Top Buys

Rank Stock Value
1
DCGO icon
DocGo
DCGO
+$1.17M
2
CHRS icon
Coherus Oncology
CHRS
+$394K
3
AXSM icon
Axsome Therapeutics
AXSM
+$336K
4
ACAD icon
Acadia Pharmaceuticals
ACAD
+$248K
5
AXDX
Accelerate Diagnostics
AXDX
+$158K

Top Sells

Rank Stock Value
1
IMGN
Immunogen Inc
IMGN
+$5.57M
2
CYTK icon
Cytokinetics
CYTK
+$1.16M
3
LQDA icon
Liquidia Corp
LQDA
+$139K

Sector Composition

Rank Sector Weight
1 Healthcare 94.27%
2 Energy 5.73%
3 Consumer Staples 0.01%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
PXD
26
DELISTED
Pioneer Natural Resource Co.
PXD
$998K 0.81%
3,800
– –
TVTX icon
27
Travere Therapeutics
TVTX
$5.33B
$941K 0.77%
122,000
– –
PGNY icon
28
Progyny
PGNY
$2.44B
$839K 0.68%
22,000
– –
KPTI icon
29
Karyopharm Therapeutics
KPTI
$168M
$709K 0.58%
31,322
– –
CYTK icon
30
Cytokinetics
CYTK
$11B
$701K 0.57%
10,000
-15,000
-60% -$1.16M
CHRS icon
31
Coherus Oncology
CHRS
$217M
$645K 0.53%
270,000
+160,000
+145% +$394K
ARVN icon
32
Arvinas
ARVN
$518M
$619K 0.5%
15,000
– –
KNSA icon
33
Kiniksa Pharmaceuticals
KNSA
$4.83B
$592K 0.48%
30,000
– –
KALV
34
DELISTED
KalVista Pharmaceuticals
KALV
$546K 0.44%
46,000
+6,000
+15% +$80K
SWTX
35
DELISTED
SpringWorks Therapeutics
SWTX
$492K 0.4%
10,000
– –
KROS icon
36
Keros Therapeutics
KROS
$199M
$463K 0.38%
7,000
– –
XENE icon
37
Xenon Pharmaceuticals
XENE
$6.32B
$431K 0.35%
10,000
– –
CGEM icon
38
Cullinan Oncology
CGEM
$1.05B
$428K 0.35%
25,114
– –
BLUE
39
DELISTED
bluebird bio
BLUE
$411K 0.34%
16,060
– –
HALO icon
40
Halozyme
HALO
$9.72B
$407K 0.33%
10,000
– –
BHVN
41
DELISTED
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
$403K 0.33%
7,365
– –
GTHX
42
DELISTED
G1 Therapeutics, Inc. Common Stock
GTHX
$346K 0.28%
80,000
– –
FOLD
43
DELISTED
Amicus Therapeutics
FOLD
$330K 0.27%
28,000
– –
SRPT icon
44
Sarepta Therapeutics
SRPT
$1.66B
$324K 0.26%
2,500
– –
AXDX
45
DELISTED
Accelerate Diagnostics
AXDX
$322K 0.26%
325,239
+100,000
+44% +$158K
AXSM icon
46
Axsome Therapeutics
AXSM
$12.4B
$319K 0.26%
+4,000
New +$336K
CSTL icon
47
Castle Biosciences
CSTL
$749M
$310K 0.25%
14,000
+4,000
+40% +$87K
XNCR icon
48
Xencor
XNCR
$1.44B
$272K 0.22%
12,300
– –
ZNTL icon
49
Zentalis Pharmaceuticals
ZNTL
$308M
$252K 0.21%
16,000
– –
WVE icon
50
Wave Life Sciences
WVE
$1.12B
$247K 0.2%
40,000
– –
1
2
3

Similar funds

RWA
Resolute Wealth Advisor Findlay, Ohio $176M AUM
BAM
Boyar Asset Management New York $176M AUM 20.04% 1-Year Est. Return
TIM
Tevis Investment Management Plano, Texas $176M AUM 18.14% 1-Year Est. Return
LWM
Lifetime Wealth Management Rockwall, Texas $176M AUM
PFA
Providence Financial Advisors Overland Park, Kansas $175M AUM
DAM
Draper Asset Management Smithtown, New York $176M AUM 37.45% 1-Year Est. Return
AF
Align Financial Hermantown, Minnesota $176M AUM
OA
Oceanside Advisors Mount Pleasant, South Carolina $175M AUM 17.96% 1-Year Est. Return

Birchview Capital's Q1 2024 Portfolio in Review

As of Q1 2024, Birchview Capital held 60 positions worth $123M, down 4% from $128M the previous quarter. Its ten largest holdings account for 68% of the portfolio.

Birchview Capital withdrew a net $4.27M in Q1 2024, closing 1 position and reducing 2 holdings. Its most notable exit was Immunogen Inc, an estimated $5.57M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 94% of assets, down from 95% a quarter earlier, followed by Energy and Consumer Staples.

Against the trend, Birchview Capital opened a new position in Axsome Therapeutics worth $319K.

  • Birchview Capital's largest Q1 2024 buy was Axsome Therapeutics: 4,000 shares worth $319K.
  • Birchview Capital added most to DocGo in Q1 2024, an estimated $1.17M increase.
  • Birchview Capital's biggest Q1 2024 reduction was Cytokinetics, cutting an estimated $1.16M.
  • Birchview Capital fully exited Immunogen Inc in Q1 2024, selling an estimated $5.57M.
  • Birchview Capital's ten largest holdings make up 68% of its $123M portfolio in Q1 2024.
  • Birchview Capital opened 2 new positions and closed 1 in Q1 2024.
  • Birchview Capital's portfolio value fell 4% quarter-over-quarter to $123M.

Based on Birchview Capital's 13F filing for Q1 2024, filed 14 May 2024.